Market Overview

Leading Companies Make Switch to Veeva OpenData to Deliver Accurate Data Faster to Field Teams


Organizations from emerging biopharma to the largest pharmaceutical
companies are improving field productivity and driving better customer

(NYSE:VEEV) today announced that more life sciences
companies are adopting Veeva
to empower their field teams with faster, accurate customer
data. Veeva OpenData provides access to approximately 16 million
healthcare professionals (HCPs) and their healthcare organizations
(HCOs) spanning 42 countries. Emerging biopharma and the largest
pharmaceutical companies are using Veeva OpenData in various regions to
increase field effectiveness and enhance customer engagement.

Accurate, actionable data was critical for Nestlé
Health Science
to improve efficiency of their sales teams. "Veeva
OpenData enables our sales reps to be more productive," said Rick Priem,
global CRM manager for Nestlé Health Science. "We have the insights we
need to better understand what is happening in the field and drive
improved customer interactions."

Specialty pharmaceutical company, Indivior,
previously had two data systems and worked from 17 different versions of
the same data source across North America and Europe. This created an
administrative burden on field reps managing customer information and
left teams uncertain if they were working from the most current data
such as physician addresses and specialty areas.

Indivior moved to Veeva OpenData for one complete source of customer
reference data to help field teams effectively and compliantly deliver
new addiction treatment information to HCPs. Now HCP data is validated
easier and faster, resulting in field teams that are confident they are
leveraging the right customer information.

"By switching to Veeva OpenData, we gained a single source of customer
data that's accurate – a major advantage in today's varying compliance
environment," said Dianne Goodburn, commercial director at Indivior.

Veeva OpenData delivers fast, up-to-date customer data so field reps can
focus on building trusted relationships with their customers. Data
stewards validate and update data change requests in hours versus the
industry average of 10 or more days.1 Through integration of
Veeva OpenData with Veeva
, a sales representative can search and download data up to 60%
faster and with 50% fewer clicks, allowing field reps to target the
right physicians and opportunities in real-time.2

"Veeva OpenData delivers quality customer data, right in CRM, to improve
our sales execution," said Dipak Bhatti, managing director at Syner-Med.
"Our sales reps can take a more targeted approach to field-based
activities, helping improve the quality of our customer interactions."

Veeva also makes it easier for companies to use and gain value from
their customer data through an ecosystem of certified
Veeva OpenData partners
. Expanded partnerships eliminate the need
for multiple third-party agreements, shortening time and reducing costs
of implementation.

"Many industry-leading companies are turning to Veeva OpenData as a
complete source of customer data to improve sales execution, maintain
compliance, and deliver accurate reporting and analytics," said Rebecca
Silver, global vice president of Veeva OpenData. "Veeva OpenData is
becoming foundational for customers of all sizes in driving greater
commercial success."

Additional Information

For more about Veeva OpenData, visit:

Connect with Veeva on LinkedIn:

Follow @veevasystems on Twitter:

Like Veeva on Facebook:

About Veeva Systems

Veeva Systems Inc. is a leader in cloud-based software for the global
life sciences industry. Committed to innovation, product excellence, and
customer success, Veeva has more than 625 customers, ranging from the
world's largest pharmaceutical companies to emerging biotechs. Veeva is
headquartered in the San Francisco Bay Area, with offices in Europe,
Asia, and Latin America. For more information, visit

Forward-looking Statements

This release contains forward-looking statements, including the market
demand for and acceptance of Veeva's products and services, the results
from use of Veeva's products and services, and general business
conditions, particularly in the life sciences industry. Any
forward-looking statements contained in this press release are based
upon Veeva's historical performance and its current plans, estimates,
and expectations, and are not a representation that such plans,
estimates, or expectations will be achieved. These forward-looking
statements represent Veeva's expectations as of the date of this press
announcement. Subsequent events may cause these expectations to change,
and Veeva disclaims any obligation to update the forward-looking
statements in the future. These forward-looking statements are subject
to known and unknown risks and uncertainties that may cause actual
results to differ materially. Additional risks and uncertainties that
could affect Veeva's financial results are included under the captions,
"Risk Factors" and "Management's Discussion and Analysis of Financial
Condition and Results of Operations," in the company's filing on Form
10-Q for the period ended

April 30, 2018. This is available on the company's website at
under the Investors section and on the SEC's website at
Further information on potential risks that could affect actual results
will be included in other filings Veeva makes with the SEC from time to

1 Veeva 2016 European Customer Data Survey

2 Veeva internal analysis

View Comments and Join the Discussion!